Latest Commercialisation News

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

EOS has reported a 126% increase in its contract backlog to $307 million in 1H 2025, driven by strong demand for its defence and space technologies despite a revenue decline. The company secured a landmark €71.4 million high energy laser weapon export contract and continues to strengthen its balance sheet.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Papyrus Australia has signed a binding term sheet with TBS Mining Solutions to produce a biodegradable version of the Collar Keeper®, marking a major step in sustainable mining innovation.

Papyrus Australia has signed a binding term sheet with TBS Mining Solutions to produce a biodegradable version of the Collar Keeper®, marking a significant step in commercialising sustainable mining products.

dorsaVi Ltd has unveiled Artemis Labs, a new subsidiary focused on developing advanced AI, sensor, and robotics technologies powered by cutting-edge RRAM. This initiative aims to transform human movement data into intelligent robotic and healthcare applications.